{"id":"W4402552559","doi":"10.1016/j.annonc.2024.08.2330","title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Hexal AG; Pharmacyclics; Genentech; Eisai; Pfizer; Innovent Biologics; Incyte; Moderna; SkylineDx; BeiGene; Les Laboratories Pierre Fabre; Sun Pharma; Regeneron Pharmaceuticals; Array BioPharma; Qbiotics; NGM Biopharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Exelixis; Sanofi; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Ipilimumab; Pembrolizumab; Oncology; Internal medicine; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004906367,0.001445596,0.00275515,0.00037469,0.0006315979,0.001966764,0.001029751,0.001736209,0.002956875],"category_scores_gemma":[0.002733659,0.000642653,0.003504574,0.0005978129,0.0008766873,0.0021466,0.0006571186,0.00465581,0.001158409],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001281278,"about_ca_system_score_gemma":0.001055988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001309459,"about_ca_topic_score_gemma":0.001899075,"domain_scores_codex":[0.9985778,0.0006522961,0.00006612569,0.0002468182,0.0001417999,0.0003152325],"domain_scores_gemma":[0.9976377,0.0005181278,0.0007618826,0.0003038049,0.0001456189,0.000632918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9078271,0.009075621,0.01723796,0.0006289296,0.006592462,0.0001619621,0.0001693597,0.001961017,0.005975298,0.000197507,0.003737239,0.04643548],"study_design_scores_gemma":[0.4705194,0.3218361,0.1810748,0.0002477362,0.01077497,0.0005488715,0.0003454594,0.002388838,0.003183725,0.0008062636,0.008151765,0.0001220246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855242,0.007271062,0.0005683088,0.0006899855,0.0002984273,0.0005112709,0.002666502,0.00005171364,0.002418494],"genre_scores_gemma":[0.9883752,0.002558235,0.0004004845,0.001316978,0.0003140926,0.000484453,0.00368773,0.00003506505,0.002827822],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004906367,"threshold_uncertainty_score":0.02594769,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07706815044565193,"score_gpt":0.4198472869789294,"score_spread":0.3427791365332774,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}